Skip to Main ContentSkip to FooterSkip to Search
Main menu
  1. Home
  2.  » 
  3. Catalent News
  4.  » Biohaven announces Expanded Access Program for Patients with ALS
RSS feed icon

Biohaven announces Expanded Access Program for Patients with ALS

Catalent’s partner, Biohaven, announces it has Initiated Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS)

Learn more